# A Study to Evaluate ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peri Mets

> **NCT04950166** · PHASE2 · COMPLETED · sponsor: **OncoNano Medicine, Inc.** · enrollment: 51 (actual)

## Conditions studied

- Peritoneal Carcinomatosis

## Interventions

- **DRUG:** pegsitacianine

## Key facts

- **NCT ID:** NCT04950166
- **Lead sponsor:** OncoNano Medicine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-30
- **Primary completion:** 2022-12-29
- **Final completion:** 2023-01-20
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04950166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04950166, "A Study to Evaluate ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peri Mets". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04950166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*